Velocity is a leading clinical research site organisation across Europe, with sites in Germany, Poland, and the U.K. Fully integrated operations and a unified technology platform ensure Velocity sites can accelerate site start-up and accurately forecast and enrol patients at scale, saving considerable time for you.


World-class sites, reliable enrollment, and high performance for clinical trials across Europe

Velocity opened its first European site in Hamburg , Germany, in mid-2022, and expanded that same year with a site Leipzig, followed by two more sites in the U.K. with the acquisition of Egin Research. In 2023, Velocity added three greenfield sites in the U.K., six sites in Poland, and four more in Germany (via acquisitions of KO-MED Centra Kliniczne, ClinMedica Research, InterMed, Klinische Forschung Berlin, The Pulmonary Research Institute at the LungenClinic Großhansdorf, and KLB Gesundheitsforschung Lübeck).

The acquisition of KO-MED, Poland’s leading site network, marked Velocity’s entrance into oncology research. The acquisition of The Pulmonary Research Institute in Germany further demonstrated Velocity’s commitment to supporting specialty research programs across Europe and worldwide.

North London Skyline.
Research sites across Europe
Investigators across Europe
Clinical trials conducted in Europe

Therapeutic and Specialty Population Expertise

Experienced Investigators, Specialists, and Research Staff

Therapeutic expertise

Specialty populations

Specialized trial support

  • Biosimilars
  • Combination products
  • Devices
  • Decentralized
  • Diagnostics
  • Hospital
  • Interventional
  • Observational
  • Overnight

The right sites.
The right investigators.
The right partner for your trials.

All Velocity sites feature experienced principal investigators supported by well-trained research staff. Geographic dispersion also supports access to critical subpopulations. Above all, Velocity's sites are built to ensure world-class quality, scalability, and productivity.